https://stock.noler.com/us/stock/pharmos-corp https://stock.noler.com/us/stock/pharmos-corp/accounts-payable https://stock.noler.com/us/stock/pharmos-corp/accrued-liabilities-current https://stock.noler.com/us/stock/pharmos-corp/activist-13d-13g-form-sc-13d https://stock.noler.com/us/stock/pharmos-corp/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/pharmos-corp/additional-paid-in-capital https://stock.noler.com/us/stock/pharmos-corp/amended-reports-10-k https://stock.noler.com/us/stock/pharmos-corp/amended-reports-10-q https://stock.noler.com/us/stock/pharmos-corp/amortization-of-financing-costs https://stock.noler.com/us/stock/pharmos-corp/cash-and-equivalents https://stock.noler.com/us/stock/pharmos-corp/cash-flow-breakdown https://stock.noler.com/us/stock/pharmos-corp/class-of-warrant-or-right-outstanding https://stock.noler.com/us/stock/pharmos-corp/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/pharmos-corp/common-stock-value https://stock.noler.com/us/stock/pharmos-corp/convertible-debt-current https://stock.noler.com/us/stock/pharmos-corp/convertible-debt-noncurrent https://stock.noler.com/us/stock/pharmos-corp/cover-page-shares-outstanding https://stock.noler.com/us/stock/pharmos-corp/current-assets https://stock.noler.com/us/stock/pharmos-corp/current-liabilities https://stock.noler.com/us/stock/pharmos-corp/debt-conversion-converted-instrument-shares-issued https://stock.noler.com/us/stock/pharmos-corp/depreciation-and-amortization https://stock.noler.com/us/stock/pharmos-corp/depreciation-and-amortization-expense https://stock.noler.com/us/stock/pharmos-corp/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/pharmos-corp/employee-benefits-and-share-based-compensation https://stock.noler.com/us/stock/pharmos-corp/general-and-administrative-expense https://stock.noler.com/us/stock/pharmos-corp/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/pharmos-corp/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/pharmos-corp/increase-decrease-in-employee-related-liabilities https://stock.noler.com/us/stock/pharmos-corp/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/pharmos-corp/insider-transactions-corporate-securities https://stock.noler.com/us/stock/pharmos-corp/insider-transactions-corporate-securities/purchases https://stock.noler.com/us/stock/pharmos-corp/insider-transactions-other https://stock.noler.com/us/stock/pharmos-corp/insider-transactions-stock-options https://stock.noler.com/us/stock/pharmos-corp/insider-transactions-warrants https://stock.noler.com/us/stock/pharmos-corp/insider-transactions-warrants/purchases https://stock.noler.com/us/stock/pharmos-corp/interest-expense https://stock.noler.com/us/stock/pharmos-corp/investing-cash-flow https://stock.noler.com/us/stock/pharmos-corp/investment-income-interest https://stock.noler.com/us/stock/pharmos-corp/late-filing-notices-nt-10-k https://stock.noler.com/us/stock/pharmos-corp/late-filing-notices-nt-10-q https://stock.noler.com/us/stock/pharmos-corp/net-change-in-cash https://stock.noler.com/us/stock/pharmos-corp/net-income https://stock.noler.com/us/stock/pharmos-corp/operating-cash-flow https://stock.noler.com/us/stock/pharmos-corp/operating-expenses https://stock.noler.com/us/stock/pharmos-corp/operating-income https://stock.noler.com/us/stock/pharmos-corp/other-expenses https://stock.noler.com/us/stock/pharmos-corp/other-income https://stock.noler.com/us/stock/pharmos-corp/other-nonoperating-expense https://stock.noler.com/us/stock/pharmos-corp/other-nonoperating-income-expense https://stock.noler.com/us/stock/pharmos-corp/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/pharmos-corp/payments-for-proceeds-from-productive-assets https://stock.noler.com/us/stock/pharmos-corp/payments-to-acquire-productive-assets https://stock.noler.com/us/stock/pharmos-corp/preferred-shares-facts https://stock.noler.com/us/stock/pharmos-corp/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/pharmos-corp/preferred-stock-shares-authorized https://stock.noler.com/us/stock/pharmos-corp/preferred-stock-shares-issued https://stock.noler.com/us/stock/pharmos-corp/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/pharmos-corp/preferred-stock-value https://stock.noler.com/us/stock/pharmos-corp/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/pharmos-corp/property-plant-equipment https://stock.noler.com/us/stock/pharmos-corp/public-float https://stock.noler.com/us/stock/pharmos-corp/research-and-development https://stock.noler.com/us/stock/pharmos-corp/retained-earnings https://stock.noler.com/us/stock/pharmos-corp/revenue-from-grants https://stock.noler.com/us/stock/pharmos-corp/sec-comment-letters-corresp https://stock.noler.com/us/stock/pharmos-corp/sec-comment-letters-upload https://stock.noler.com/us/stock/pharmos-corp/sec-filings-10-c https://stock.noler.com/us/stock/pharmos-corp/sec-filings-10-k https://stock.noler.com/us/stock/pharmos-corp/sec-filings-10-q https://stock.noler.com/us/stock/pharmos-corp/sec-filings-15-12g https://stock.noler.com/us/stock/pharmos-corp/sec-filings-25-nse https://stock.noler.com/us/stock/pharmos-corp/sec-filings-8-a12g https://stock.noler.com/us/stock/pharmos-corp/sec-filings-8-k https://stock.noler.com/us/stock/pharmos-corp/sec-filings-ars https://stock.noler.com/us/stock/pharmos-corp/sec-filings-def-14a https://stock.noler.com/us/stock/pharmos-corp/sec-filings-defa14a https://stock.noler.com/us/stock/pharmos-corp/sec-filings-pre-14a https://stock.noler.com/us/stock/pharmos-corp/sec-filings-prec14a https://stock.noler.com/us/stock/pharmos-corp/sec-filings-prer14a https://stock.noler.com/us/stock/pharmos-corp/sec-filings-prrn14a https://stock.noler.com/us/stock/pharmos-corp/sec-filings-regdex https://stock.noler.com/us/stock/pharmos-corp/secondary-offerings-form-424b2 https://stock.noler.com/us/stock/pharmos-corp/secondary-offerings-form-424b3 https://stock.noler.com/us/stock/pharmos-corp/secondary-offerings-form-424b5 https://stock.noler.com/us/stock/pharmos-corp/secondary-offerings-form-aw https://stock.noler.com/us/stock/pharmos-corp/secondary-offerings-form-effect https://stock.noler.com/us/stock/pharmos-corp/secondary-offerings-form-pos-am https://stock.noler.com/us/stock/pharmos-corp/secondary-offerings-form-s-1 https://stock.noler.com/us/stock/pharmos-corp/secondary-offerings-form-s-3 https://stock.noler.com/us/stock/pharmos-corp/secondary-offerings-form-s-8 https://stock.noler.com/us/stock/pharmos-corp/secondary-offerings-form-s-8-pos https://stock.noler.com/us/stock/pharmos-corp/shareholders-equity https://stock.noler.com/us/stock/pharmos-corp/shares-authorized https://stock.noler.com/us/stock/pharmos-corp/shares-issued https://stock.noler.com/us/stock/pharmos-corp/stock-award-number-of-shares-available-for-grant https://stock.noler.com/us/stock/pharmos-corp/stock-award-rsu-nonvested-grant-date-fair-value https://stock.noler.com/us/stock/pharmos-corp/stock-based-compensation https://stock.noler.com/us/stock/pharmos-corp/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/pharmos-corp/stock-issued-new-shares-sold https://stock.noler.com/us/stock/pharmos-corp/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/pharmos-corp/stock-options-outstanding-number https://stock.noler.com/us/stock/pharmos-corp/stockholders-equity-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/pharmos-corp/total-assets https://stock.noler.com/us/stock/pharmos-corp/total-liabilities https://stock.noler.com/us/stock/pharmos-corp/total-liabilities-and-equity https://stock.noler.com/us/stock/pharmos-corp/treasury-stock-shares https://stock.noler.com/us/stock/pharmos-corp/treasury-stock-value https://stock.noler.com/us/stock/pharmos-corp/weighted-average-number-of-share-outstanding-basic-and-diluted